Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Research Center for Traceability and Standardization of TCMs, School of Traditional Chinese Pharmacy, China Pharmaceutical University, 639 Longmian Road, Nanjing, 211198, PR China.
J Ethnopharmacol. 2021 Jan 10;264:113381. doi: 10.1016/j.jep.2020.113381. Epub 2020 Sep 15.
Recently, a new drug combination GRS comprising ginsenoside Rb1 (G-Rb1), ruscogenin (R-Rus) and schisandrin (S-SA) was screened based on ShengMai preparations, which exhibited a prominent cardioprotective effects against myocardial ischemia/reperfusion (MI/R) injury.
To investigate their systemic and individual mechanism of each compound in combination GRS.
The mice model of MI/R and hypoxia/reoxygenation (H/R)-induced cardiomyocytes injury were performed to explore the respective characteristics of each compound in GRS against myocardial injury.
Each component in the combination GRS attenuated MI/R injury as evidenced by decreased myocardial infarct size, ameliorated histological features, and improved biochemical indicators. Meanwhile, ingredient G, R and S in combination also individually performed a significant decrease of apoptotic index in MI/R mice and H/R-induced cardiomyocytes injury. Mechanistically, component G in GRS could markedly increase the ATP content in cardiomyocytes through activation of AMPKα phosphorylation. Interestingly, the anti-apoptotic actions of G were profoundly attenuated by knockdown of AMPKα, while no alteration was observed on composition R and S. Moreover, component R in GRS significantly reduced the IL-6 and TNF-α mRNA expression, as well as the content of IL-6 via the modulation of NF-κB signaling pathway. Further, component S exhibited the most powerful anti-oxidative capacity in GRS and remarkably decreased the production of MDA and ROS, and potential mechanisms might at least in part through activating the Akt-14-3-3 signaling pathway and inhibiting the phosphorylation of Bad and ERK1/2.
Our results indicated that the respective mechanism of each compound in combination GRS against MI/R injury might closely associated with energy metabolism modulation, suppression of inflammation and oxidative stress.
最近,一种新的药物组合 GRS 被筛选出来,该组合包含人参皂苷 Rb1(G-Rb1)、鲁斯可苷元(R-Rus)和五味子甲素(S-SA),其基于生脉制剂,对心肌缺血/再灌注(MI/R)损伤表现出明显的心脏保护作用。
研究组合 GRS 中各化合物的系统和个体机制。
采用 MI/R 模型和缺氧/复氧(H/R)诱导的心肌细胞损伤模型,探讨各化合物在 GRS 中的各自特点及其对心肌损伤的作用机制。
组合 GRS 中的每个成分都减轻了 MI/R 损伤,表现为心肌梗死面积减小、组织学特征改善和生化指标改善。同时,组合中的成分 G、R 和 S 也分别显著降低了 MI/R 小鼠和 H/R 诱导的心肌细胞损伤中的细胞凋亡指数。在机制上,GRS 中的成分 G 通过激活 AMPKα 的磷酸化,显著增加了心肌细胞中的 ATP 含量。有趣的是,G 的抗凋亡作用被 AMPKα 的敲低显著减弱,而成分 R 和 S 则没有改变。此外,GRS 中的成分 R 显著降低了 IL-6 和 TNF-α mRNA 的表达以及 IL-6 的含量,通过调节 NF-κB 信号通路。进一步,GRS 中的成分 S 表现出最强的抗氧化能力,显著降低 MDA 和 ROS 的产生,其潜在机制至少部分通过激活 Akt-14-3-3 信号通路和抑制 Bad 和 ERK1/2 的磷酸化。
我们的结果表明,组合 GRS 中各化合物对 MI/R 损伤的各自机制可能与能量代谢调节、抑制炎症和氧化应激密切相关。